首页> 外国专利> GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF G-PROTEIN BETA 3 SUBUNIT POLYMORPHISM

GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF G-PROTEIN BETA 3 SUBUNIT POLYMORPHISM

机译:心脏衰竭的遗传风险评估:G蛋白β3亚基多态性遗传变异的影响

摘要

The invention provides methods for treating various indications and diseases in a patient in need thereof, wherein the patient has a C825T polymorphism in the G protein beta3 subunit (GNB3), comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.
机译:本发明提供了用于在有需要的患者中治疗各种适应症和疾病的方法,其中所述患者在G蛋白β3亚基(GNB3)中具有C825T多态性,包括对患者给药(i)至少一种抗氧化剂化合物或药物其可接受的盐; (ii)至少一种一氧化氮增强化合物; (iii)可选地,目前用于治疗心血管疾病的最佳疗法。在一个实施方案中,抗氧化剂是肼苯哒嗪化合物或其药学上可接受的盐,而一氧化氮增强化合物是硝酸异山梨酯和/或硝酸异山梨酯。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号